Home > Publications database > Long-term survival trends in solid cancers in the Nordic countries marking timing of improvements. > print

001     186485
005     20241220120852.0
024 7 _ |a 10.1002/ijc.34416
|2 doi
024 7 _ |a pmid:36571455
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:140600328
|2 altmetric
037 _ _ |a DKFZ-2022-03206
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hemminki, Kari
|0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
|b 0
|e First author
|u dkfz
245 _ _ |a Long-term survival trends in solid cancers in the Nordic countries marking timing of improvements.
260 _ _ |a Bognor Regis
|c 2023
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1678881980_29492
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C020# / 2023 May 1;152(9):1837-1846
520 _ _ |a Survival studies are an important indicator of the success of cancer control. We analyzed the 5-year relative survival in 23 solid cancers in Denmark, Finland, Norway and Sweden over a 50-year period (1970-2019) at the NORDCAN database accessed from the International Agency for Research on Cancer website. We plotted survival curves in 5-year periods and showed 5-year periodic survival. The survival results were summarized in 4 groups: 1) cancers with historically good survival (>50% in 1970-74) which include melanoma and breast, endometrial and thyroid cancers; 2) cancers which constantly improved survival at least 20 % units over the 50 year period, including cancers of the stomach, colon, rectum, kidney, brain and ovary; 3) cancer with increase in survival >20 % units with changes taking place in a narrow time window, including oral, oropharyngeal, testicular and prostate cancers; 4) the remaining cancers with <20 % unit improvement in survival including lung, esophageal, liver, pancreatic, bladder, soft tissue, penile, cervical and vulvar cancers. For cancers in groups 1 and 2, the constant development implied multiple improvements in therapy, diagnosis and patient care. Cancers in group 3 included testicular cancers with known therapeutic improvements but for the others large incidence changes probably implied that cancer stage (prostate) or etiology (oropharynx) changed into a more tractable form. Group 4 cancers included those with dismal survival 50 years ago but a clear tendency upwards. In 17 cancers 5-year survival reached between 50 and 100 % while in only 6 cancers it remained at below 50%. This article is protected by copyright. All rights reserved.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a early diagnosis
|2 Other
650 _ 7 |a periodic survival
|2 Other
650 _ 7 |a prognosis
|2 Other
650 _ 7 |a relative survival
|2 Other
650 _ 7 |a treatment
|2 Other
700 1 _ |a Försti, Asta
|0 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
|b 1
|u dkfz
700 1 _ |a Liska, Vaclav
|b 2
700 1 _ |a Kanerva, Anna
|b 3
700 1 _ |a Hemminki, Otto
|b 4
700 1 _ |a Hemminki, Akseli
|0 0000-0001-7103-8530
|b 5
773 _ _ |a 10.1002/ijc.34416
|g p. ijc.34416
|0 PERI:(DE-600)1474822-8
|n 9
|p 1837-1846
|t International journal of cancer
|v 152
|y 2023
|x 0020-7136
909 C O |o oai:inrepo02.dkfz.de:186485
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2022-11-25
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-25
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2022
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2022
|d 2023-10-21
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
920 0 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21